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CLINICAL STUDIES
Abstract: The present work looks into the different aspects of glucose homeostasis in the elderly patients in 
comparison to healthy younger subjects and patients with type 2 diabetes mellitus, relying on intravenous 
glucose tolerance test.
A clinicobiochemical study was carried out comprising forty apparently healthy non-diabetic non-obese old 
individuals (mean age 65±4.8 years). Forty type 2 diabetic patients compared to thirty healthy young subjects. 
The senile group had no family history of diabetes. Cases with renal, hepatic, gastrointestinal, or endocrine 
abnormalities were excluded from the study. Intravenous glucose tolerance test (ivGTT) was done with sampling 
at 0, 5, 10, 15, 30, 45, and 60 min after glucose load and the following estimations were undertaken: glucose 
constant decay (KG), glucose and insulin area under the curve, insulnogenic index, first phase insulin response, 
insulin resistance index and fractional insulin clearance.
The senile and diabetic groups, when compared to the control, had non-significantly different fasting plasma 
glucose in senile group but it was higher in diabetic patients, while fasting serum insulin was significantly higher 
in the studied groups than in healthy control group. The senile group showed significant reduction in glucose 
tolerance (KG 1.36±0.3%/min), decreased insulin sensitivity index (5.19±1.4 10-4 min-1 /[uU/ml]) and marked 
reduction of first phase insulin response (2.45±0.78 uIU/ml per mg/dl), when compared with the control group. 
However, the degree of glucose intolerance and insulin insensitivity of the senile group was still significantly 
less than of type 2 diabetic patients. This study revealed that the insulin resistance seems to be characteristic 
feature of normal aging process and senility could be considered as an inevitable risk factor for glucose 
intolerance and metabolic syndrome with its accompanying health hazards. Insulin secretion, insulin clearance 
and interaction between insulin and target tissues are defective in elderly subjects. These functions are 
intermediate between healthy controls and type 2 diabetic patients and may predispose the elderly population to 
the risk of impaired glucose tolerance or diabetes mellitus with its attendant macrovascular and microvascular 
complications.
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Introduction
As the human community develops, the group of aged population constitutes a larger 
percent of the total population. This particular group of people is characterized by increased 
incidence of macrovascular complications that are similar to those described in the metabolic 
syndrome or type 2 diabetes mellitus (DM). Moreover, it is well known that the incidences as 
well as the prevalence of type 2 diabetes and impaired glucose tolerance (IGT) is more common 
in old age people’ (1). According to the Third National Health and Nutrition Examination Survey 
(NHANS III), conducted from 1984 to 1994, the prevalence of impaired glucose tolerance, 
impaired fasting glucose and diabetes mellitus is increasing with advancing age; type 2 DM was 
evident in >20% while IGT was found in another 20% of those between 60 and 74 years of age
[2] Moreover, approximately one half of old diabetics are unaware of having diabetes [2].
The mechanism of age-related glucose intolerance is not yet completely clear. The 
interaction of many factors associated with aging likely contributes to the alteration of glucose 
tolerance in this population. These factors include increased adiposity, decreased physical 
activity, medications, coexisting illnesses, and insulin secretory defects associated with the 
aging process [3]. Insensitivity to the actions of insulin at the postreceptor level, inadequate 
secretion of insulin and decreased hepatic sensitivity to insulin's action in suppressing glucose 
output also occur with advancing age [4].
It is, thus, of utmost interest to investigate the change in glucose homeostasis in the 
elderly persons and to explore its mechanism. The present work looks into the different aspects 
of glucose homeostasis in the elderly patients in comparison to healthy younger subjects and 
patients with type 2 diabetes mellitus, relying on intravenous glucose tolerance test.
Subjects and Methods
Forty apparently healthy non-diabetic, non-obese old individuals (mean age 65±4.8 
years) were selected for the study. They had no family history of DM and they were mostly 
relatives of patients presented to outpatient and inpatient department of Mansoura University 
Hospitals. Thirty healthy young individuals with no family history of DM and 40 subjects with 
type 2 diabetes mellitus were included as normal- and ill-control groups, respectively. Cases 
with renal, hepatic, gastrointestinal, obesity or endocrinal abnormalities were excluded from the 
study. All studied cases were matched sex and body mass index (BMI). All cases were subjected 
to thorough medical history taking and examination with stress upon mean blood pressure and 
body mass index, features of chronic diseases such as renal, hepatic gastrointestinal or endocrine 
diseases. In addition to routine investigations such as hemoglobin, hematocrite value, serum 
albumin, ALT levels, and serum cholesterol, triglyceride, LDL-cholesterol, HDL-cholesterol. 
Intravenous glucose tolerance test [5]
All studied cases were not given drugs or foods that potentially affect glucose tolerance 3 
days before the test and a mixed diet containing 130-200 grams carbohydrates was taken for a 
similar period. The test was carried in the morning after 12-hour fasting. The cases were 
admitted to hospital and rested in bed for more than 30 minutes, and a G-18 intravenous canula
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 was placed in a superficial vein in each arm and they were kept open with slow infusion of 
normal saline. A fasting blood sample (6-8 ml) was withdrawn from one canula for fasting 
levels. Thereafter, a bolus of glucose 0.5 grams/kg body weight from 25% dextrose solution 
(2ml/kg) was injected in the contralateral canula   over   2-4 minutes.   Following this, blood 
samples of 2-3 ml each were drawn from the first canula at 5, 10, 15, 30, 45, and 60 minutes 
after the glucose injection. All blood samples were kept in ice until separated by centrifugation, 
10 microliters of the sera were used for estimation of glucose levels while the remaining part of 
each sample was divided into 2 aliquots and kept frozen at 20qC until the time of insulin assay. 
Before insulin assay, the samples were allowed to thaw at room temperature and mixed by 
gentle swirling or inversion. Serum glucose was determined by the glucose oxidase enzyme 
procedures (Biomerieux-Vitek Inc. Missouri, USA) while serum insulin assay was carried out 
by a solid phase enzyme amplified sensitivity immunoassay- the Medgenix-INS-EASIA 
immunoenzymetric ELISA procedure (Bio Source Europe S.A., Nivelles, Belgium). 
Mathematics and Calculations
Tests of Plasma Glucose Metabolic State
- Fasting and time curve of plasma glucose.
- Glucose Constant Decay (KG): It is the rate of glucose disappearance in response to I.V. 
   glucose load. It is calculated according to Bergman [6]: kG=69.3/t½, where t½ is the half-life of 
   glucose in minutes. The results are expressed as % per minute
- Area under the Curve for glucose (AUCglu; mg/dl.min), both early (0-10 min) and late (10-60
   min): is calculated by adding the area under the curve between each pair of consecutive
   measurements using the trapezium rule[7].
Tests for Assessment of Insulin Release State
- Area under the curve for insulin (AUCins; uIU/ml.min) both early (0-10 min) and late (10-60
   min): is calculated by the trapezium rule [7] .
- Acute Insulin response (AIR; uIU/ml): is the average of the increases of plasma levels of
insulin within 0-15 min after the I.V. glucose bolus above the basal value [8] .
Tests for Assessment of Pancreatic Beta Cell Function
-  Insulinogenic index (IGI; uIU/ml.min per mg/dl.min): is calculated by dividing AUCins over
    AUCglu. It is used to relate the response of beta cells (as assessed by changes in serum insulin 
    concentrations) to every change in plasma glucose concentration [9] .
-  First phase insulin response (uIU/ml.min per mg/dl): is calculated as the insulin area above
     basal over 0-10 minutes divided by the glucose peak above basal [10] .
-  Beta cell function %: is calculated using homeostatic model assessment (HOMA) [11]  as
     20ubasal insulin mU.L-1/ (basal glucose mmol.L-1-3.5)
Tests for Assessment of Insulin-target Tissue Interaction
- Insulin Sensitivity Index: is determined by the KG divided by the total area under the curve for
   insulin (AUCins). The results are expressed as 10-4 min-1 / [uU/ml] [10].
- Insulin resistance index (IRI) [12] is calculated as AUCins/KGu1000.
- Relative insulin resistance - index [11]: is calculated as basal insulin (in uIU/ml)u10/22.5uln
   basal glucose (in mmol/l).
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-  The homeostasis model assessment (HOMA) insulin resistance (HOMA-R) [11]. It is calculated
    as follows: 
   HOMA-R = [basal insulin mU/L) x basal glucose (mmol/L)]/22.5
- Quantitative insulin sensitivity check index (QUICKI) [13]. QUICKI = 1/ (log [basal insulin
  (mU/L)] + log [basal glucose (mmol/L)]          
    
Tests for Assessment of insulin catabolic state
- Second phase insulin response (uIU/ml.min per mg/dl.min) is calculated as the
  insulin area above basal over 10 - 60 minutes divided by the glucose peak above 
   basal [10] .
- Fractional insulin clearance (%min-1): is calculated by dividing 69.3/t½ of
   Insulin [8]. 
Statistical Methods
All data are expressed as mean values ± standard deviations. Comparison by 2 means 
was carried out by the student t-test for non-paired samples. One way analysis of variance 
(ANOVA) is used to study the difference between the mean values of several groups. The 
contingency table and chi-square test analyze the frequency of distribution of subjects between 
different groups. A probability p-value of <0.05 was considered to be statistically significant. 
All statistical calculations were carried out with the SPSS computer program for windows. 
Results
The age, sex distribution, body mass index (BMI) and mean blood pressure (MBP) of the 
senile, healthy control and type 2 diabetic groups are shown in Table (1). There is no significant 
difference in sex distribution and BMI between the examined groups. The mean blood pressure 
higher in the senile group compared to the other groups. 
Table 2 shows some routine hematological and laboratory data. The senile group has 
significantly lower hemoglobin and HDL-cholesterol compared to each of the other two groups. 
           Table 1: Clinical data of Senile (G1), Healthy Control (G2) and type II DM (G3) groups
Clinical Data Senile group(G1)
N=40
Healthy control 
group
(G2)
N=30
Type 2 DM 
group
(G3)
N=40
p-value
Age: mean±SD (yrs) 65.6±4.8 44.6±3.5 49.2±6.8 <0.001*
Male/Female 20/20 15/15 20/20 >0.05**
BMI: mean±SD 25.8±2.3 24.4±3.6 26.2±2.7 >0.05*
MBP: Mean±SD (mmHg) 111.6±14.8 93.3±3.9 106.1±13.3 <0.01*
   * One way ANOVA test  ** Chi-square test
Abbreviations: N, number; BMI, body mass index; DM, diabetes mellitus; MBP, mean blood pressure 
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     Table 2: Routine laboratory parameters of senile (G1), normal healthy control (G2) and type II DM (G3) groups
Laboratory Parameters
Senile group
(G1)
mean±SD
Normal control
(G2)
mean±SD
Type II DM
(G3)
mean±SD
(G1) vs (G2) (G2) vs (G3)
Hb (g/dl) 11±2.3 13.5±0.7 13±1.5 P>0.05 P>0.05
Hct (%) 33±6.5 40±3.3 37±4.7 P<0.01* P<0.05*
ALT (U/ml) 29.6±12 26±2.9 28±10.2 P>0.05 P>0.05
S. Albumin (g/dl) 3.8±0.48 4.1±0.28 4.1±0.4 P>0.05 P>0.05
S. Creatinine
 (mg/dl) 1.6±0.6 1.0±0.02 1.0±0.3 P<0.01* P<0.001*
S. Cholesterol
 (mg/dl) 194±47 164±18.8 200±35 P>0.05 P>0.05
LDL (mg/dl) 128±44 101±16 127±34 P>0.05 P>0.05
HDL (mg/dl) 33±7.2 47.2±6.9 43±8.6 P<0.001* P<0.001*
S. triglycerides
 (mg/dl) 144±58 76±18.3 153±48 P<0.01* P>0.05
Abbreviations: Hb; hemoglobin, Hct; hematocrite, S.; serum, SD; standard deviation, vs; versus
*One way ANOVA significant difference at P<0.05
     
Fasting plasma glucose is higher in the senile group in comparison to the healthy non-
senile group; although the difference does not reach the level of statistical significance (92±15.7 
vs. 84±7.1 mg/dl, p>0.05; Table 3). 
Fasting plasma insulin, on the other hand, is significantly higher in the senile group than 
that in the normal group, while it is significantly lower than that in type 2 diabetic patients; the 
fasting plasma insulin of the senile group is nearly halfway between those of the normal and of 
the type 2 diabetic  groups (Table 3). The same table shows that the early area under the curve 
for glucose is higher in the senile group than the healthy control group although the differences 
are not statistically significant. However, the late area under the curve for glucose is highly 
significantly higher in the senile subjects than the control ones. The glucose disappearance rate, 
on the other hand, is significantly lower in the senile group than that of the control group but still 
significantly higher than that of the Type 2 diabetic group (Table 3).
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Table 3: Comparison between glucose tolerance parameters in the senile (G1), normal (G2) and type II DM (G3) groups
Laboratory Parameters
Senile group
(G1)
mean±SD
Normal
control
(G2)
mean±SD
Type II DM
(G3)
mean±SD
G1 vs G2 G2 vs G3
Fasting plasma glucose (mg/dl) 92±15.1 84.7±7.1 222.3±51.2 P>0.05 P<0.001*
Fasting plasma Insulin (uIU/ml) 14.6±5.1 7.4±1.8 23.3±9.2 P<0.001* P<0.001*
AUCglu (mg/dl.min)
Early (0-10 min)
Late (10-60 min)
2624±512
10616±2098
2391±231
8247±780
35648±835
17007±3905
P>0.05
    P<0.001*
P<0.001*
P<0.001*
KG  (%/min) 1.36±0.3 2.23±0.02 0.75±0.07 P<0.001* P<0.001*
Abbreviations: AUC: area under the curve. Vs: versus. KG: Glucose Constant Decay
*One way ANOVA significant difference at P<0.05
Table 4: Comparison between pancreatic beta-cell functions in the senile (G1), control (G2), and type II DM (G3) groups
Functional indices
Senile group
(G1)
mean±SD
Normal
control
(G2)
mean±SD
Type ll DM
(G3)
mean±SD
G1 vs G2 G3 vs G2
AUCIns(uIU/ml.min)
Early (0-10)
Late (10-60)
502±140
2251±668
669±196
2500±772
310±147
1493±862
P<0.01*
P>0.05
P<0.001*
     P<0.01*
Acute insulin response
(AIR; uIU/ml)
43.4±13.9 71.3±22.3 10.4±9.9 P<0.001* P<0.001*
First phase insulin response 
(uIU/ml per mg/dl)
2.45±0.78 3.320±88 1.78±1.02 P<0.01* P<0.05*
Insulinogenic Index 0.21±0.06 0.30±0.07 0.09±0.02 P<0.01* P<0.001*
ȕ-cell function % 162.1±85.9 100±12 42.5±16.3 P<0.05* P<0.001*
Abbreviations: vs: versus, AUC: Area under the curve
*One way AOVA significant difference at P<0.05
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Data concerning the insulin release and estimated beta cell function are shown in (Table 
4). Both the area under the insulin curve, the acute insulin response, the first phase insulin 
response, and the insulinogenic index are significantly lower in the senile group than those of 
the healthy group, while they were significantly higher then those of the type 2 diabetic patients. 
The percentage of beta-cell function is, however, significantly higher in the senile group than 
both other groups. Results of tests of insulin-target tissue interaction and insulin catabolic state 
are shown in (Table 5); insulin sensitivity index and the quantitative insulin sensitivity check 
index is highly significantly decreased in the senile group compared to the healthy subjects 
while still significantly higher than those of the type 2 diabetic patients are. On the opposite site, 
in the senile group, insulin resistance index, relative insulin resistance, and the homeostatic 
model assessment insulin resistance data are highly significantly higher than those in the healthy 
control are but  still significantly lower that those in the type 2 diabetic patients. Fractional 
insulin clearance is significantly lower in the senile subjects compared to that of the healthy 
control, while it is non-significantly different from that of type 2 diabetic patients.  
Table 5: Tests of insulin-target tissue interaction and insulin catabolic state in the senile (G1) in comparison to the 
                                                             control (G2) and type 2 diabetic (G3) groups
Insulin Sensitivity
Parameters
Senile group
(G1)
mean±SD
Normal
control
(G2)
mean±SD
Type II DM
(G3)
mean±SD
G1 vs V2 G2 vs G3
Second phase insulin response 
(uIU/ml.min per mg/dl.min) 17.6±5.6 23.6±6.43 8.03±5.2 P<0.01 P<0.001
Insulin Sensitivity Index (10-4
min-1 /[uU/ml]) 5.19±1.4 7.63±2.2 2.54±3.0 P<0.01 P<0.001
Insulin resistance index 2.06±0.57 1.41±0.4 3.82±2.3 P<0.01 P<0.01
Relative insulin
 resistance index 3.96±1.3 2.14±0.5 4.24±1.8 P<0.001 P>0.05
HOMA-IR 3.42±1.44 1.55±0.41 12.44±4.71 P<0.001 P<0.001
QUICKI 0.56±0.081 0.67±0.05 0.42±0.03 P<0.001 P<0.001
Fractional insulin
 clearance (%min-1) 1.13±0.7 1.97±.90 0.97±0.59 P<0.05 P>0.05
Abbreviations: HOMA-IR: Homeostatic Model Assessment Insulin Resistance
QUICKI: Quantitative Insulin Sensitivity Check Index.
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Discussion
It is now a common concept that glucose tolerance progressively declines with age, 
resulting in a high prevalence of type 2 diabetes and impaired glucose tolerance in the older 
population [1]. Old age is associated with reduced glucose effectiveness, increased hepatic 
insulin extraction, and reduced glucose sensitivity in the second phase of insulin secretion. Old 
age is also associated with high plasma pancreatic polypeptide levels but no change in plasma 
leptin or glucagon. The impaired elimination of glucose in old subjects with maintained normal 
glucose tolerance is suggested to be caused mainly by reduced glucose effectiveness and 
impaired second phase insulin [14]. Alteration of pancreatic beta-cell function independent of that 
seen with type 2 diabetes mellitus occurred in relation to aging. This may be a predisposing 
factor to the development of impaired glucose tolerance or type 2 diabetes mellitus in elderly 
subjects, that is, independent of obesity [15].  
However, the mechanism of age-related glucose intolerance is not yet completely clear, 
although a better understanding of the metabolic alterations associated with aging is important 
for the continued development of preventive and therapeutic strategies for this population at high 
risk for the development of diabetes [3]. The present study tries to define abnormalities in glucose 
homeostasis in the senile population and to dissect their pathophysiological mechanism. An 
intravenous glucose tolerance test has been carried out with a time course determination of 
plasma glucose and insulin changes in a group of non-obese, non-diabetic aged subjects. These 
data are compared to data from younger healthy subjects and type 2 diabetic patients that were 
carried out in parallel to them. 
Although the senile persons were not fatter than the younger ones, their fasting plasma 
glucose and plasma insulin tended to be higher than those of the healthy subjects are. However, 
they remained significantly below the levels detected in the type 2 diabetic patients. This finding 
agrees with previously reported data from population studies that fasting glucose levels increase 
with age by ~1-2 mg/dl per decade [16]. It also accords in essence with the data of Third National 
Health and Nutrition Examination Survey (NHANS III), conducted from 1984 to 1994, in which 
the prevalence of impaired glucose tolerance, impaired fasting glucose and diabetes mellitus is 
increasing with advancing age [2].  Following the intravenous glucose challenge, the plasma 
glucose showed significantly decreased rate of clearance with greater area under the glucose 
curve in the senile group compared to the healthy control. These findings are in harmony with 
the report of Anders [17] who indicated that postchallenge glucose levels increase with age by ~6-
9 mg/dl per decade. The interaction of many factors associated with aging likely contributes to 
the alteration of glucose tolerance in this population. These factors may include increased 
adiposity, decreased physical activity, medications, coexisting illness, and insulin secretory 
defects associated with the aging process [18]. 
In the present study, tests of insulin release are significantly lower in the senile persons 
than the healthy control, with significantly decreased acute insulin response, first phase insulin 
secretion, and insulinogenic index. The early area under the insulin curve was significantly 
decreased while the change in the late part of the curve was not significantly different from the 
healthy control group. These changes in insulin secretion were still significantly better than the 
respective data in the type 2 diabetic patients. Many previous studies examined the effects of 
aging on pancreatic beta-cell function in humans, although there is a great deal of variability in
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the outcomes of these studies [19] . This variability may be due to multiple factors including the 
small magnitude of the age effect, the use of different measures of insulin secretion, and 
confounding factors associated with aging such as obesity, decreased physical activity, and 
concomitant insulin resistance [3]. 
A delayed insulin response in the 1st hour after oral glucose load was described in older 
people compared with young adults, despite the older adults having higher (but not diabetic) 
fasting and postchallenge glucose levels [20] . On the other hand, other studies have noted normal 
or increased insulin levels in response to oral glucose with advancing age [21, 22]. Imbeault et al
[23] provided evidence that visceral obesity, more than age per se, correlates with glucose 
intolerance in middle-aged subjects; and aging does not influence in vitro adipose tissue glucose
uptake. The authors suggest that aging per se does not influence glucose homeostasis [23].
Similarly, Maneatis et al [24]  found no significant correlation between age, when adjusted for 
differences in body weight and physical activity, and plasma glucose response in men, and 
differences in age could account for no more than 6% of the variability in glucose response in 
women.
Normal insulin secretion is pulsatile and orderly, with both rapid, low-amplitude pulses, 
which occur every 8-15 min, and ultradian pulses, which have larger amplitude and occur every 
60-140 min [25]. In the fasting state, older subjects have been found to have more disorderly 
insulin release, with decreased amplitude and mass of rapid insulin pulses and reduced frequency 
of ultradian pulses [26] compared with young subjects. 
Potential explanations for variable results when aging-related defects in beta-cell 
function are assessed include the lack of age standardization and differences in age-related 
variables such as insulin resistance, obesity, and physical activity in young and old subjects. 
Findings of similar insulin secretion in young and old subjects may suggest relative defects in 
pancreatic beta-cell function in light of concomitant insulin resistance and relative glucose 
intolerance in the older population. When young and old subjects are matched for these 
variables, reduced beta-cell function with aging has been detected [8]. 
In the present work, however, the test for percent beta cell function, which relies on the 
basal fasting state only (the homeostasis model assessment, HOMA) showed significantly 
augmented beta cell function in the senile group compared to both the healthy as well as the type 
2 diabetic groups. This might denote an inherent weakness in this test as it does not account for 
the proper compensatory response of the beta cell to any associated insulin resistance [27]. All 
performed tests for assessing insulin-target tissue interaction, in the present study, showed 
significant abnormalities. Tests for insulin sensitivity were significantly blunted while those for 
insulin resistance were significantly augmented in the senile group compared to the healthy 
control group. However, these data were significantly better than the respective ones in the type 
2 diabetic patients. These results suggest major defect in the response of target tissue to the 
released insulin. These observations are supported with those of DeFronzo [21, 28]. They also 
accord with Stout [4]  who denoted that the progressive deterioration of glucose tolerance with 
advancing age was related, at least partly, to insensitivity to the action of insulin at the post 
receptor level; an effect that is made worse by obesity, renal failure or the ingestion of certain 
drugs, or may be lessened by increased physical activity [4] .
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Imbeault et al [23] provided evidence that visceral obesity, more than age per se, correlates 
with glucose intolerance in middle-aged subjects; and aging does not influence in vitro adipose 
tissue glucose uptake. The authors suggest that aging per se does not influence glucose 
homeostasis [23]. This is in agreement with the results of Maneatis et al [25] who found no 
significant correlation between age, when adjusted for differences in body weight and physical 
activity, and plasma glucose response in men, and differences in age could account for no more 
than 6% of the variability in glucose response in women. Similarly, when differences in overall 
and regional obesity as well as fitness (assessed by both history and maximal aerobic capacity) 
were taken into account, Shimokata et al [29] could find no effect of age on plasma glucose 
responses to oral glucose in the 17–39 and 40–59 age groups, while age had a significant effect 
of plasma glucose in the 60-90 years of age. However, the senile group of the present study had 
insignificantly lower body weight compared to the healthy control group; although this does not 
preclude the presence of visceral obesity as the percentage of muscle mass tends to decrease 
while body fat increase with age[17]. 
Physical fitness may also be an important determinant of glucose homeostasis. It has 
been shown that 50% of the variability in insulin-mediated glucose disposal in healthy Pima 
Indians and subjects of European ancestry was related to differences in fitness and fatness, with 
each contributing to 25% of the variance [30]. Evidence that glucose tolerance was significantly 
worse in older Taiwanese office workers than in laborers of the same age provides indirect 
support for the lack of fitness playing an important role in the glucose intolerance associated 
with aging. Indeed there was no loss of glucose tolerance with age in the laborers [31]. 
Fractional clearance of insulin was found to be significantly decreased in the senile 
group compared to the healthy control; it was not significantly different from the type 2 diabetic 
patients. This is in agreement with previous studies [32-34]. Thus, it may be deduced that 
comparable insulin levels in old and young people could reflect relative insulin secretory defects 
in old people in light of diminished insulin clearance and relative glucose intolerance in this
group. 
In conclusion, insulin secretion, insulin clearance and interaction between insulin and 
target tissues are defective in elderly subjects. These functions are intermediate between healthy 
controls and type 2 diabetic patients and may predispose the elderly population to the risk of 
impaired glucose tolerance or diabetes mellitus with its attendant macrovascular and 
microvascular complications. Further studies are needed to delineate the fine mechanisms 
underlying the deterioration in each step of glucose homeostasis abnormalities. It may be 
recommended that every effort should be exerted to prevent any possible predisposing factors 
for insulin resistance or beta-cell dysfunction, in order to forestall the rapidly growing epidemic 
of type 2 diabetes, beginning at a young age. One important way for such a goal is to prevent 
fatness and encourage fitness. 
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